Monte Rosa Therapeutics, Inc. GLUE Interest Income (Expense), Nonoperating
Interest Income (Expense), Nonoperating at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s interest income (expense), nonoperating?
- Monte Rosa Therapeutics, Inc. (GLUE) reported interest income (expense), nonoperating of $5.59M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s interest income (expense), nonoperating changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s interest income (expense), nonoperating increased by 62.6% year-over-year, from $3.44M to $5.59M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s interest income (expense), nonoperating?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s interest income (expense), nonoperating has grown at a 309.6% compound annual growth rate (CAGR), from $46K to $12.94M.